These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 16300476)
81. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695 [No Abstract] [Full Text] [Related]
82. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Giembycz MA Drugs; 2000 Feb; 59(2):193-212. PubMed ID: 10730545 [TBL] [Abstract][Full Text] [Related]
83. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Lagente V; Martin-Chouly C; Boichot E; Martins MA; Silva PM Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():131-6. PubMed ID: 15962112 [TBL] [Abstract][Full Text] [Related]
84. KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4. Sasaki K; Manabe H Inflamm Res; 2004 Jan; 53(1):31-7. PubMed ID: 15021978 [TBL] [Abstract][Full Text] [Related]
85. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Giembycz MA; Smith SJ Curr Pharm Des; 2006; 12(25):3207-20. PubMed ID: 17020529 [TBL] [Abstract][Full Text] [Related]
86. Phosphodiesterases: the journey towards therapeutics. Torphy TJ; Page C Trends Pharmacol Sci; 2000 May; 21(5):157-9. PubMed ID: 10885973 [No Abstract] [Full Text] [Related]
87. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685 [TBL] [Abstract][Full Text] [Related]
88. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors. Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490 [TBL] [Abstract][Full Text] [Related]
89. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system. Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621 [TBL] [Abstract][Full Text] [Related]
91. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238 [TBL] [Abstract][Full Text] [Related]
92. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087 [TBL] [Abstract][Full Text] [Related]
93. Increased building block access through collaboration. Helal CJ; Bartolozzi A; Goble SD; Mani NS; Guzman-Perez A; Ohri AK; Shi ZC; Subramanyam C Drug Discov Today; 2018 Aug; 23(8):1458-1462. PubMed ID: 29571837 [No Abstract] [Full Text] [Related]
99. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. Ochiana SO; Bland ND; Settimo L; Campbell RK; Pollastri MP Chem Biol Drug Des; 2015 May; 85(5):549-64. PubMed ID: 25283372 [TBL] [Abstract][Full Text] [Related]
100. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors. Amata E; Bland ND; Hoyt CT; Settimo L; Campbell RK; Pollastri MP Bioorg Med Chem Lett; 2014 Sep; 24(17):4084-9. PubMed ID: 25127163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]